By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
Limited Rain Chances in Brazil Boost Coffee Prices - 2Volunteers aiding humpback whale stranded in Baltic get death threats
- 3Last supermoon of the year, the cold moon, seen across the U.S.: See the photos
- 4What are the health benefits of whole milk for kids?
- 5Find the Lively Food Markets of South America
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- NASA to bring astronauts home from space station early due to a medical issue
- Tech for Wellbeing: Applications and Devices for a Better You
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
- ‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- Over 250,000 cases of shredded cheese recalled over possible metal fragments
